CN1124273C - Fluoric diphenylacetylene compounds and preparing process and application thereof - Google Patents
Fluoric diphenylacetylene compounds and preparing process and application thereof Download PDFInfo
- Publication number
- CN1124273C CN1124273C CN00115133A CN00115133A CN1124273C CN 1124273 C CN1124273 C CN 1124273C CN 00115133 A CN00115133 A CN 00115133A CN 00115133 A CN00115133 A CN 00115133A CN 1124273 C CN1124273 C CN 1124273C
- Authority
- CN
- China
- Prior art keywords
- compound
- fluorine
- cdcl
- nmr
- diphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a diphenylacetylene compound containing fluorine, which has the molecular formula as the following figure, wherein R or R'=C<1 to 12> alkyl radicals; X=H or F; a is like the right lower figure. The present invention is prepared by a Heck reaction or a condensation reaction. The compound has the characteristics of wide liquid crystal phase range, low viscosity and good fat solubility, and furthermore, the compound of the present invention is new liquid crystal material.
Description
The present invention relates to a kind of fluorine-containing (diphenyl) acetylene compounds.This compound one side connects alkoxyl group, and opposite side connects oxygen, sulphur, heterogeneous ring compounds such as boron.This compound can make respectively by Heck reaction or condensation reaction, is a kind of novel liquid crystal material.
Liquid crystal material needs low melting point, high clearing point, and the mesomorphic phase wide ranges, chemical stability is good, the degree of birefringence height, viscosity is low, and is fat-soluble good.Haruyoshi Takatsu, people such as Kodaira have reported a kind of tolane nematic liquid crystalline cpd (U.S.P.4705870,1987).People such as Wen Jianxun have reported the liquid crystalline cpd (CN 9,210 84444.7) of fluorine-containing phenyl ring, introduce acetylene bond between ring and ring, can improve degree of birefringence, use transformation temperature lower, and a wider range is fat-soluble good.People such as Wen Jianxun have also reported and have utilized the synthetic fluorine-containing tolane liquid crystalline cpd (CN 00111985.0) that contains the liquid crystalline cpd (CN 97106778.3) of cyclohexyl and perfluoro-benzene-ring and contain side chain of olefinic oxygen of Heck reaction.Because the increasingly extensive application of liquid crystal material, people still expect constantly to explore the liquid crystal material of excellent property.
The purpose of this invention is to provide a kind of new fluorine-containing (diphenyl) acetylene compounds.Connect alkoxyl group and heterocycle respectively in the compound both sides.
Purpose of the present invention also provides the method for preparing above-claimed cpd.
Another object of the present invention provides the purposes that above-claimed cpd is used for liquid crystal material.
Fluorine-containing (diphenyl) acetylene compounds of the present invention has following molecular formula:
R or R '=C wherein
1-12Alkyl, X=H or F,
As following compound:
Deng.
The preparation of fluorine-containing (diphenyl) acetylene compounds of the present invention can be made respectively by Heck reaction or condensation reaction, further describes as follows:
The oxygen that contains of the present invention, sulphur, the fluorine-containing (diphenyl) acetylene compounds of heterocyclic such as boron can be by molecular formula:
The palkoxy benzene acetylene compound and molecular formula be I or
Halogenide makes through the Heck reaction, and reaction formula is:
Or
R wherein, R ', X and A are all ditto described.
Specifically, above-mentioned fluorine-containing (diphenyl) acetylene compounds, halogenide is at palladium compound, CuX and nitrogenous organic ligand exist down, to reflux temperature, react 0.5-100h in room temperature, the above-claimed cpd mol ratio is followed successively by 1: 1-10: 0.01-0.2: 0.02-0.40: 0-100.Described palladium compound is two (trihydrocarbyl phosphine) dihalide palladium, two (trihydrocarbyl phosphine) palladium, and two (trihydrocarbyl phosphine) Palladous nitrate, common described alkyl is C
1-12Alkyl, described nitrogenous organic ligand is to have C
1-12The tertiary amine of alkyl, secondary amine, primary amine, pyridine, bipyridine etc.The having of nitrogenous organic ligand helps the carrying out that react, and the above-mentioned halogenide and the mol ratio of nitrogenous organic ligand are recommended as 1: 1-10, recommend to use triethylamine.
The oxygen that contains of the present invention, sulphur, the fluorine-containing (diphenyl) acetylene compounds of heterocyclic such as boron also can be made by condensation reaction, and reaction formula is as follows:
Or
R wherein, R ', X are all ditto described, Y or Z=O or S.Described condensation reaction is in organic solvent, and under the reflux conditions, molecular formula is
Benzaldehyde compound, or molecular formula is
Aryl boric acid, tosic acid and molecular formula are
Heteroatoms alkylol cpd, mol ratio are 1: 0.01-0.2: 1-10, the reaction times is 0.5-24h.Recommend mol ratio to be followed successively by 1: 0.01: 1.1.
Because the existence of sulphur atom in the thia ring, palladium compound is poisoned and the reduction reaction yield, so adopt alcohol condensation under Catalyzed by p-Toluenesulfonic Acid of aldehyde cpd and sulfur-bearing, can obtain the fluorine-containing (diphenyl) acetylene compounds of higher yields, have more practical value.
Fluorine-containing (diphenyl) acetylene compounds of the present invention is simple synthetic method not only, and is a kind of novel good TN, STN and TFT liquid crystal display material.Have low melting point, high clearing point, the mesomorphic phase wide ranges, chemical stability is good, the degree of birefringence height, viscosity is low, and fat-soluble characteristics such as good are suitable for suitability for industrialized production and application.
The present invention will be helped to understand by following embodiment, but content of the present invention can not be limited.
Embodiment 1
Preparation:
With I or
200mg,
100-150mg, two (triphenylphosphine) Palladous chlorides or Palladous nitrate 5-15mg, CuI 10-20mg, triethylamine 5-20ml is at room temperature to 60 ℃ stirring 10-24h, high pressure liquid chromatography or fluorine spectrum track to reaction and finish, filter, add organic solvent extraction, the organic phase dried over sodium sulfate, boil off solvent, column chromatography for separation.The result is as shown in the table:
Compound 1:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 18H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MS m/z (%): 406 (M
+, 100.0), 222 (43.35) ultimate analyses: calculated value .C, 79.77; H, 8.43%.
Sequence number | R | Productive rate % |
1 2 3 4 5 6 | C 4H 9 C 5H 11 C 6H 13 C 7H 15 C 8H 17 C 12H 25 | 51 57 53 54 54 49 |
Analytical value .C, 79.91; H, 8.53%. compound 2:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 20H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MS m/z (%): 420 (M
+, 100.0), 222 (27.96) ultimate analyses: calculated value .C, 79.96; H, 8.63%.
Analytical value .C, 80.23; H, 8.78%. compound 3:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 22H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MS m/z (%): 434 (M
+, 100.0), 222 (30.26) ultimate analyses: calculated value .C, 80.14; H, 8.81%.
Analytical value .C, 80.21; H, 8.91%. compound 4:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 24H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MS m/z (%): 448 (M
+, 100.0), 222 (54.99) ultimate analyses: calculated value .C, 80.32; H, 8.99%.
Analytical value .C, 80.39; H, 9.08%. compound 5:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 26H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MSm/z (%): 462 (M
+, 100.0), 222 (63.67) ultimate analyses: calculated value .C, 80.48; H, 9.15%.
Analytical value .C, 80.64; H, 9.24%. compound 6:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.78 (m, 34H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.5Hz); 3.95-4.01 (m, 2H); 4.22-4.27 (m, 2H); 5.41 (s, 1H); 6.84-6.90 (m, 2H); 7.44-7.53 (m, 6H) .MSm/z (%): 518 (M
+, 100.0), 222 (58.21) ultimate analyses: calculated value .C, 81.03; H, 9.71%.
Analytical value .C, 80.89; H, 9.85%.
With I or
0.1mmol,
0.1-0.15mmol, two (triphenylphosphine) Palladous chlorides or two (tri octyl phosphine) Palladous nitrate 5-15mg, CuI10-20mg adds triethylamine or pyridine 10ml, and at room temperature to 60 ℃ stirring 24h, product concentrates through column chromatography for separation.The result is as follows:
Compound 7:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 18H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.4Hz); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19FNMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MS m/z (%): 478 (M
+, 72.32), 294 (100.0) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 15.88%.
Sequence number | R | Productive rate % |
7 8 | C 4H 9 C 5H 11 | 48 48 |
10 11 12 | C 7H 15 C 8H 17 CH 3 | 46 48 52 |
Analytical value .C, 67.58; H, 6.17; F, 16.29%. compound 8:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 20H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.4Hz); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19F NMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MS m/z (%): 492 (M
+, 84.02), 294 (100.0) ultimate analyses: calculated value .C, 68.28; H, 6.55; F, 15.43%.
Analytical value .C, 68.29; H, 6.49; F, 15.49%. compound 9:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 22H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.4Hz); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19F NMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MS m/z (%): 506 (M
+, 61.51), 294 (100.0) ultimate analyses: calculated value .C, 68.76; H, 6.76; F, 15.00%.
Analytical value .C, 68.82; H, 6.72; F, 15.26%. compound 10:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 24H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.4Hz); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19F NMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MSm/z (%): 520 (M
+, 100.0), 294 (94.52) ultimate analyses: calculated value .C, 69.21; H, 6.97; F, 14.60%.
Analytical value .C, 69.12; H, 6.91; F, 14.88%. compound 11:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 26H); 2.15 (m, 1H); 3.54 (t, 2H, J=11.4Hz); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19F NMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MS m/z (%): 534 (M
+, 99.82), 294 (89.57) ultimate analyses: calculated value .C, 69.64; H, 7.16; F, 14.21%.
Analytical value .C, 69.72; H, 7.11; F, 14.54%. compound 12:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.88-1.80 (m, 11H); 2.15 (m, 1H); 3.54 (m, 3H); 4.22-4.29 (m, 4H); 5.42 (s, 1H); 7.48-7.59 (m, 4H).
19F NMR δ
F(60MHz; CDCl
3TFA): 60.0 (m, 2F); 79.6 (m, 2F) MS m/z (%): 436 (M
+, 100.0), 294 (95.34) ultimate analyses: calculated value .C, 66.05; H, 5.54; F, 17.41%.
Analytical value .C, 66.31; H, 5.51; F, 17.32%.
Embodiment 3
Preparation: adopt
With
Be raw material, operation is with embodiment 1, and the result is as follows:
Compound 13:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (m, 18H); 2.09 (m, 1H); 3.51 (t, 2H, J=11.4Hz); 3.96-4.00 (m, 2H); 4.21-4.26 (m, 2H); 5.35 (s, 1H); 6.86-7.52 (m, 6H).
19FNMR δ
F(60MHz; CDCl
3TFA): 30.0 (s, 2F) MS m/z (%): 442 (M+, 100.0), 258 (29.62) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 8.59%.
Sequence number | R | Productive rate % |
13 14 15 16 17 | C 4H 9 C 5H 11 C 6H 13 C 7H 15 C 8H 17 | 53 57 51 58 58 |
Analytical value .C, 67.58; H, 6.17; F, 8.40%. compound 14:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (m, 20H); 2.09 (m, 1H); 3.51 (t, 2H, J=11.4Hz); 3.96-4.00 (m, 2H); 4.21-4.26 (m, 2H); 5.35 (s, 1H); 6.86-7.52 (m, 6H).
19F NMR δ
F(60MHz; CDCl
3TFA): 30.0 (s, 2F) MS m/z (%): 456 (M
+, 100.0), 258 (79.59) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 8.32%.
Analytical value .C, 67.58; H, 6.17; F, 8.42%. compound 15:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (m, 22H); 2.09 (m .1H); 3.51 (t, 2H, J=11.4Hz); 3.96-4.00 (m, 2H); 4.21-4.26 (m, 2H); 5.35 (s, 1H); 6.86-7.52 (m, 6H).
19FNMR δ
F(60MHz; CDCl
3TFA): 30.0 (s, 2F) MSm/z (%): 470 (M
+, 100.0), 258 (73.76) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 8.07%.
Analytical value .C, 67.58; H, 6.17; F, 8.04%. compound 16:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (m, 24H); 2.09 (m, 1H); 3.51 (t, 2H, J=11.4Hz); 3.96-4.00 (m, 2H); 4.21-4.26 (m, 2H); 5.35 (s, 1H); 6.86-7.52 (m, 6H).
19F NMR δ
F(60MHz; CDCl
3TFA): 30.0 (s, 2F) MS m/z (%): 484 (M
+, 100.0), 258 (75.15) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 7.84%..
Analytical value .C, 67.58; H, 6.17; F, 7.92%. compound 17:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (m, 26H); 2.09 (m, 1H); 3.51 (t, 2H, J=11.4Hz); 3.96-4.00 (m, 2H); 4.21-4.26 (m, 2H); 5.35 (s, 1H); 6.86-7.52 (m, 6H).
19F NMR δ
F(60MHz; CDCl
3TFA): 30.0 (s, 2F) MS m/z (%): 498 (M
+, 100.0), 258 (75.30) ultimate analyses: calculated value .C, 67.77; H, 6.32; F, 7.62%.
Analytical value .C, 67.58; H, 6.17; F, 7.46%.
Embodiment 4
Preparation: adopt
With
Be raw material, operation is with embodiment 2, and the result is as follows:
Compound 18:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.81 (m, 18H); 2.11 (m, 1H); 3.52 (t, 2H, J=11.4Hz); 4.21-4.31 (m, 4H); 5.34 (s, 1H); 7.08-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 514 (M
+, 31.38), 330 (100.0.) ultimate analysis: calculated value .C, 63.03; H, 5.49; F, 22.16%.
Sequence number | R | Productive rate % |
18 19 20 21 22 | C 4H 9 C 5H 11 C 6H 13 C 7H 15 C 8H 17 | 45 43 43 46 42 |
Analytical value .C, 62.95; H, 5.41; F, 22.45%. compound 19:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.81 (m, 20H); 2.12 (m, 1H); 3.51 (t, 2H, J=11.5Hz); 4.21-4.30 (m, 4H); 5.36 (s, 1H); 7.09-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 528 (M
+, 25.55), 330 (100.0.) ultimate analysis: calculated value .C, 63.63; H, 5.72; F, 21.57%.
Analytical value .C, 63.48; H, 5.64; F, 21.45%. compound 20:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.83 (m, 22H); 2.13 (m, 1H); 3.52 (t, 2H, J=11.5Hz); 4.21-4.30 (m, 4H); 5.37 (s, 1H); 7.10-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 542 (M
+, 23.12), 330 (100.0.) ultimate analysis: calculated value .C, 64.20; H, 5.94; F, 21.01%.
Analytical value .C, 63.90; H, 5.85; F, 21.08%. compound 21:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.88 (m, 24H); 2.12 (m, 1H); 3.52 (t, 2H, J=11.5Hz); 4.21-4.30 (m, 4H); 5.36 (s, 1H); 7.10-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 556 (M
+, 26.11), 330 (100.0.) ultimate analysis: calculated value .C, 64.74; H, 6.16; F, 20.48%.
Analytical value .C, 64.60; H, 6.13; F, 20.84%.J=11.5Hz); 4.21-4.30 (m, 4H); 5.36 (s, 1H); 7.10-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 556 (M
+, 26.11), 330 (100.0.) ultimate analysis: calculated value .C, 64.74; H, 6.16; F, 20.48%.
Analytical value .C, 64.60; H, 6.13; F, 20.84%. compound 22:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.81 (m, 26H); 2.12 (m, 1H); 3.52 (t, 2H, J=11.4Hz); 4.21-4.30 (m, 4H); 5.37 (s, 1H); 7.10-7.12 (m, 2H).
19F NMR δ
F(60MHz; CDCl
3TFA): 28.6 (s, 2F); 59.8 (m, 2F); 79.9 (m, 2F) MS m/z (%): 570 (M
+, 18.37), 330 (100.0.) ultimate analysis: calculated value .C, 65.25; H, 6.36; F, 19.98%.
Analytical value .C, 65.37; H, 6.42; F, 19.87%.
Embodiment 5
The preparation of compound 23: will
250mg, C
6H
13CH (CH
2OH)
2170mg, tosic acid 5-20mg, acetone 20ml places reaction flask, reflux 2 hours, removal of solvent under reduced pressure, column chromatography for separation, the productive rate with 82% gets compound 23.Compound 23:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.87-1.82 (22H); 2.16 (m, 1H); 3.78-3.85 (t, 2H, J=10.2Hz); 3.95-3.99 (t, 2H, J=6.6Hz); 4.17-4.22 (m, 2H); 6.85-6.98 (m, 4H); 7.43-7.45 (m, 2H) ppm.
19F NMR δ
F(60MHz; CDCl
3TFA): 25.2 (s, 2F) ppm.MS m/z (%): 468 (M
+, 100.0), 398 (57.19). ultimate analysis: calculated value .C, 71.80; H, 7.53%.
Analytical value .C, 71.79; H, 7.42%.
Embodiment 6
The preparation of compound 24: 2H, J=6.55Hz); 5.12 (s, 1H); 6.85-7.51 (m, ArH, 6H) ppm.MS m/z (%): 452 (M
+, 100.0). ultimate analysis: calculated value .C, 74.29; H, 8.02%.
Analytical value .C, 74.47; H, 7.81%.
Embodiment 7
The preparation of compound 25: adopt
Be raw material, operation is with embodiment 6, and the result is as follows: compound 25:
1H NMR δ
H(300MHz; CDCl
3TMS): 0.89-1.91 (20H); 2.74-3.18 (m, 4H); 3.97 (t, 2H, J=6.55Hz); 5.72 (s, 1H); 6.85-7.51 (m, ArH, 6H) ppm.MS m/z (rel.int.): 436 (M
+, 100.0). ultimate analysis: calculated value .C, 77.02; H, 8.31%.
Analytical value .C, 77.22; H, 8.29%.
Embodiment 8
Adopt orthogonal polarizing microscope the part of compounds of embodiment 1 to 7 to be carried out phase research, the phase transition property that in heating and cooling process, occurs.During their transformation behavior was listed in the table below, wherein C represented crystal, and N represents nematic phase, and I represents isotropic liquid, and Recr represents recrystallization.From table, can find out that the mesomorphic phase scope of this compounds is very wide.
The compound sequence number | Phase transition property |
1 | Cr104.4N216.3I201.9N92.7Recr |
2 | Cr100.2N205.5I200.1N89.2Recr |
3 | Cr94.9N201.1I197.9N92.0Recr |
4 | Cr98.4N192.9I188.8N95.6Recr |
5 | Cr100.9N188.8I186.4N97.5Recr |
7 | Cr77.3N176.9I175.0N66.4Recr |
8 | Cr65.2N167.8I166.0N51.2Recr |
9 | Cr58.7N163.0I160.9N44.7Recr |
10 | Cr58.7N155.3I153.5N46.1Recr |
11 | Cr59.2N153.3I152.0N42.5Recr |
13 | Cr94.3N188.5I180.3N88.7Recr |
14 | Cr86.3N177.9I176.3N73.9Recr |
15 | Cr94.4N157.5I156.8N75.4Recr |
16 | Cr97.2N158.5I156.8N73.8Recr |
17 | Cr85.0N165.0I163.6N78.4Recr |
18 | Cr87.2N167.1I165.1N61.8Recr |
19 | Cr74.2N155.7I154.0N56.4Recr |
20 | Cr66.2N153.0I151.0N43.3Recr |
21 | Cr60.3N145.2I143.7N49.7Recr |
22 | Cr63.4N143.6I142.0N60.5Recr |
23 | Cr68.3N118.1I116.5N55.7Recr |
24 | Cr119.6N195.2I192.9N91.4Recr |
25 | Cr109.6N172.7I170.9N79.3Recr |
Claims (7)
1. fluorine-containing tolane compound is characterized in that having following molecular formula:
R or R '=C wherein
1-12Alkyl, X=H or F, A
5. fluorine-containing (diphenyl) acetylene compounds as claimed in claim 1 is characterized in that molecular formula is:
R wherein, R ' and X are described with claim 1.
6. the preparation method of a fluorine-containing (diphenyl) acetylene compounds as claimed in claim 1 is characterized in that making respectively with following method:
(1). by
The substitutedphenylethynyl compounds, Br or
Halogenide at palladium compound, CuI exists down, makes through the Heck reaction;
(2). in organic solvent and room temperature to reflux temperature, by
Aldehyde cpd, or
Boronic acid compounds, tosic acid and molecular formula are
The condensation reaction of heteroatoms alkylol cpd make, mol ratio is 1: 0.01-0.2: 1-10, reacted 0.5-24 hour;
R wherein, R ' and X are described with claim 1, Y=O or S, Z=O or S.
7. the purposes of a fluorine-containing (diphenyl) acetylene compounds as claimed in claim 1 is characterized in that being used for liquid crystal material.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN00115133A CN1124273C (en) | 2000-03-24 | 2000-03-24 | Fluoric diphenylacetylene compounds and preparing process and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN00115133A CN1124273C (en) | 2000-03-24 | 2000-03-24 | Fluoric diphenylacetylene compounds and preparing process and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1271712A CN1271712A (en) | 2000-11-01 |
CN1124273C true CN1124273C (en) | 2003-10-15 |
Family
ID=4584602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00115133A Expired - Fee Related CN1124273C (en) | 2000-03-24 | 2000-03-24 | Fluoric diphenylacetylene compounds and preparing process and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1124273C (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524394A (en) * | 2012-07-04 | 2014-01-22 | 华南师范大学 | Synthetic method and application of fluorine-containing azacyclo-alkyne liquid crystal compound |
CN105693588B (en) * | 2016-03-14 | 2018-05-18 | 华南师范大学 | Fluorine-containing pyrroles's diphenyl acetylene class organic solid fluorescent chemicals and preparation method and use |
CN114989204A (en) * | 2022-06-16 | 2022-09-02 | 西北工业大学 | Preparation method of tolane liquid crystal state cross-linking agent for glucose response self-repairing gel |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4705870A (en) * | 1984-01-23 | 1987-11-10 | Dainippon Ink And Chemicals, Inc. | Tolan-type nematic liquid crystalline compounds |
-
2000
- 2000-03-24 CN CN00115133A patent/CN1124273C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4705870A (en) * | 1984-01-23 | 1987-11-10 | Dainippon Ink And Chemicals, Inc. | Tolan-type nematic liquid crystalline compounds |
Also Published As
Publication number | Publication date |
---|---|
CN1271712A (en) | 2000-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7842845B2 (en) | Process for the preparation of ring compounds | |
KR970006720B1 (en) | A liquid crystal composition | |
CN1832911A (en) | Method for producing alkenone ethers | |
GB2046742A (en) | Dioxanylphenyl benoate liquid crystal compounds | |
CN1097762A (en) | Contain the phosphono of acrylate and/or methacrylate based group-and fluorinated carboxylic ester class of phosphinocarboxylic acid and its production and use | |
CN1124273C (en) | Fluoric diphenylacetylene compounds and preparing process and application thereof | |
CN1096788A (en) | The phosphono of hydroxyl and/or mercapto groups-and phosphinocarboxylic acid's fluorinated carboxylic ester class and its production and use | |
US5055220A (en) | Dicyclohexylethylene derivatives | |
CN1127465C (en) | Fluoric bis(diphenyl)acetylene compounds and preparing process and usage thereof | |
JPH0341473B2 (en) | ||
JP2701078B2 (en) | Allyl tolan compounds | |
CN1308279C (en) | Purification method of 6,10,14-trimethyl-5E, 9E, 13-pentadecatricene-2-ketone | |
CN1101444C (en) | Fluoric diphenylacetylene liquid crystal compound containing side chain of olifinic oxygen and its preparing process | |
KR950011236B1 (en) | Liquid crystal material | |
EP0351822B1 (en) | Tricyclic cyclohexenyl cyclohexane derivative | |
JP4007462B2 (en) | Pyridinium-type ionic compound derivative, its production method and liquid crystal substance | |
CN1061972C (en) | 2-substituted oxylacetic acid derivant, preparation trifluoromethyl and its appliance | |
CN115477571A (en) | 2-phenyl-1, 3, 4-trifluoro-6, 7,10, 11-tetra (alkoxy) triphenylene discotic liquid crystal and synthesis | |
JP6489369B2 (en) | Process for producing compound having difluoromethyl ether skeleton and intermediate compound for producing the same | |
JP2775475B2 (en) | Allylcyclohexyltrane compound | |
CN1229119A (en) | Ferroelectric type fluorine-containing steroid liquid crystal, preparation method and its use | |
CN1112355C (en) | Difluore methane-sulfonic acid metal reagent, and its synthetic method and use | |
KR20050088094A (en) | Method for producing naphthalene derivatives | |
CN1634942A (en) | Stabilized silver sulfonate complex of organo-phosphine, method for synthesizing and use thereof | |
CN117886677A (en) | Synthesis method of allyl trifluoroethyl ether compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |